Induction of myelin antigen-specific suppressor T cell

The submitted target name, "Immune system modulation via induction of suppressor T-cells specific to myelin antigens," refers not to a specific molecule or receptor, but rather a therapeutic immunological strategy that leverages the induction of antigen-specific suppressor (regulatory) T cells—typically CD8+ T cells or, in some contexts, CD4+ regulatory T cells—against myelin antigens such as myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte glycoprotein (MOG)[1][2][3][4][6]. This approach is under investigation for the treatment of multiple sclerosis (MS) and other autoimmune demyelinating diseases. Oral or systemic exposure to myelin antigens can promote the generation of these regulatory T cells, which, upon encountering their cognate antigen in the context of the central nervous system, secrete transforming growth factor beta (TGF-β1) or other immunosuppressive cytokines to suppress effector T-cell responses[1][2][3]. The approach is antigen-specific, aiming to induce tolerance without globally suppressing the immune system. However, this is a functional pathway, not a canonical drug target, and therefore does not map to a unique molecule, gene, or protein.

Other names

Suppressor T-cell induction against myelin antigensImmune tolerance via myelin-specific T-cell inductionMyelin basic protein-specific regulatory T-cell responseMyelin antigen tolerization

Induction of antigen-specific regulatory (suppressor) T cells—mainly CD8+ or CD4+ Tregs—which secrete immunosuppressive cytokines (e.g., TGF-β), leading to suppression of pathogenic immune responses specific to myelin antigens[1][2][3][6]